Abstract
The B-lymphocyte stimulator BLyS is one of the key regulators of B cell survival and proliferation. Consistent with this function, high BLyS levels in the serum and/or in affected tissues have been documented in several autoimmune and lymphoproliferative diseases. In patients with mixed cryoglobulinemic syndrome (MCsn), BLyS serum levels are significantly elevated and correlate with markers of HCV-associated B-cell lymphoproliferation. BlyS is also increased, however, in HCV-infected individuals without MCsn. Thus, HCV infection appears to be a crucial, early trigger of BLyS up-regulation. BLyS expression induced by HCV infection or by other pathogenetic events may therefore favor the development of autoimmune and lymphoproliferative features. While the etiologic role of chronic infection is well established in MCsn, such information is lacking in other autoimmune diseases, in which the role of a putative infectious trigger is strongly hypothesized. Accordingly, BLyS up-regulation in HCV-positive MC is an important model linking viral infection, B cell proliferation, and autoimmune disease. Besides direct targeting of the infectious trigger HCV and the B-cell autoimmune/lymphoproliferative disorder, indirect B-cell targeting might likewise prove effective in the treatment of HCV-related MCsn.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Moore PA, Belvedere O, Orr A et al (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285(5425):260–263
Shu HB, Hu WH, Johnson H (1999) TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol 65(5):680–683
Schneider P, MacKay F, Steiner V et al (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189(11):1747–1756
Nardelli B, Belvedere O, Roschke V et al (2001) Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97(1):198–2045
Huard B, Arlettaz L, Ambrose C et al (2004) BAFF production by antigen-presenting cells provides T cell co-stimulation. Int Immunol 16(3):467–475
Schaumann DH, Tuischer J, Ebell W et al (2007) VCAM-1-positive stromal cells from human bone marrow producing cytokines for B lineage progenitors and for plasma cells: SDF-1, flt3L, and BAFF. Mol Immunol 44(7):1606–1612
Ohata J, Zvaifler NJ, Nishio M et al (2005) Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 174(2):864–870
Krumbholz M, Theil D, Derfuss T et al (2005) BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201(2):195–200
Ittah M, Miceli-Richard C, Gottenberg JE et al (2008) Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR- and type-I IFN-dependent and -independent pathways. Eur J Immunol 38(4):1058–1064
Xu W, He B, Chiu A et al (2007) Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat Immunol 8(3):294–303
Ogden CA, Pound JD, Batth BK et al (2005) Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt’s lymphoma. J Immunol 174(5):3015–3023
Batten M, Groom J, Cachero TG et al (2000) BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 192(10):1453–1466
Thien M, Phan TG, Gardam S et al (2004) Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20(6):785–798
Zhang W, Wen L, Huang X et al (2008) hsBAFF enhances activity of NK cells by regulation of CD4(+) T lymphocyte function. Immunol Lett 120(1–2):96–102
Shu H-B, Johnson H (2000) B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1. Proc Natl Acad Sci USA 97:9156–9161
Mackay F, Schneider P (2008) TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev 19(3–4):263–276
Thompson JS et al (2001) BAFF-R, a novel TNF receptor that specifically interacts with BAFF. Science 293:2108–2111
Treml JF, Hao Y, Stadanlick JE, Cancro MP (2009) The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys 53(1):1–16
Yu G et al (2000) APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol 1:252–256
Mackay F, Schneider P, Rennert P, Browning J (2003) BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 21:231–264
Woodland RT, Fox CJ, Schmidt MR et al (2008) Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood 111(2):750–760
Fu L, Lin-Lee YC, Pham LV et al (2009) BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells. Blood 113(19):4627–4636
Gross JA et al (2001) TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 15:289–302
Mackay F, Woodcock SA, Lawton P et al (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190(11):1697–1710
Batten M, Fletcher C, Ng LG et al (2004) TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 172(2):812–822
Groom J, Kalled SL, Cutler AH et al (2002) Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren’s syndrome. J Clin Invest 109(1):59–68
Cheema GS, Roschke V, Hilbert DM, Stohl W (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44:1313–1319
Mariette X, Roux S, Zhang J et al (2003) The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren’s syndrome. Ann Rheum Dis 62(2):168–171
Stohl W (2003) SLE – systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res Ther 5(3):136–138
Bosello S, Youinou P, Daridon C et al (2008) Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 35(7):1256–1264
Matsushita T, Hasegawa M, Matsushita Y et al (2007) Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases. Exp Dermatol 16(2):87–93
Thangarajh M, Gomes A, Masterman T et al (2004) Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis. J Neuroimmunol 152(1–2):183–190
Mackay IR, Groom J, Mackay CR (2003) Levels of BAFF in serum in primary biliary cirrhosis and autoimmune diabetes. Autoimmunity 35(8):551–553
Fabris M, Visentini D, De Re V et al (2010) Elevated B cell-activating factor of the tumour necrosis factor family in coeliac disease. Scand J Gastroenterol 42(12):1434–1439
Fabris M, Grimaldi F, Villalta D et al (2010) BLyS and April serum levels in patients with autoimmune thyroid diseases. Autoimmun Rev 9(3):165–169
Becker-Merok A, Nikolaisen C, Nossent HC (2006) B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 15(9):570–576
Pers JO, Daridon C, Devauchelle V et al (2005) BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 1050:34–39
Szodoray P, Alex P, Jonsson MV et al (2005) Distinct profiles of Sjögren’s syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol 117(2):168–176
Jonsson MV, Szodoray P, Jellestad S et al (2005) Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren’s syndrome. J Clin Immunol 25(3):189–201
Neusser MA, Lindenmeyer MT, Edenhofer I et al (2011) Intrarenal production of B-cell survival factors in human lupus nephritis. Mod Pathol 24(1):98–107
Cancro MP (2006) The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis 65(Suppl 3):iii34–iii36
Ota M, Duong BH, Torkamani A et al (2010) Regulation of the B cell receptor repertoire and self-reactivity by BAFF. J Immunol 185(7):4128–4136
Toubi E, Gordon S, Kessel A et al (2006) Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun 27(2):134–139
Fabris M, Quartuccio L, Sacco S et al (2007) B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. Rheumatology (Oxford) 46(1):37–43
Sène D, Limal N, Ghillani-Dalbin P et al (2007) Hepatitis C virus-associated B-cell proliferation–the role of serum B lymphocyte stimulator (BLyS/BAFF). Rheumatology (Oxford) 46(1):65–69
Tarantino G, Marco VD, Petta S et al (2009) Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection. J Viral Hepat 16(6):397–405
Giannini C, Gragnani L, Piluso A et al (2008) Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? Blood 112(10):4353–4354
Novak AJ, Slager SL, Fredericksen ZS et al (2009) Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. Cancer Res 69(10):4217–4224
Nossent JC, Lester S, Zahra D et al (2008) Polymorphism in the 5′ regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjogren’s syndrome. Rheumatology (Oxford) 47(9):1311–1316
De Vita S, Quartuccio L, Fabris M (2008) Hepatitis C virus infection, mixed cryoglobulinemia and BLyS upregulation: targeting the infectious trigger, the autoimmune response, or both? Autoimmun Rev 8(2):95–99
De Re V, De Vita S, Gasparotto D et al (2002) Salivary gland B cell lymphoproliferative disorders in Sjögren’s syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkins’s lymphomas. Eur J Immunol 32(3):903–910
Lavie F, Miceli-Richard C, Quillard J et al (2004) Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren’s syndrome. J Pathol 202(4):496–502
Varin MM, Le Pottier L, Youinou P et al (2010) B-cell tolerance breakdown in Sjögren’s syndrome: focus on BAFF. Autoimmun Rev 9(9):604–608
Quartuccio L, Fabris M, Moretti M et al (2008) Resistance to Rituximab therapy and local BAFF overexpression in Sjögren’s syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open Rheumatol J 2:38–43
Novak AJ, Grote DM, Stenson M et al (2004) Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 104(8):2247–2253
Ju S, Wang Y, Ni H et al (2009) Correlation of expression levels of BLyS and its receptors with multiple myeloma. Clin Biochem 42(4–5):387–399
Tecchio C, Nadali G, Scapini P et al (2007) High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma. Br J Haematol 137(6):553–559
Mackay F, Tangye SG (2004) The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers. Curr Opin Pharmacol 4(4):347–354
Landau DA, Rosenzwajg M, Saadoun D et al (2009) The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders. Ann Rheum Dis 68(3):337–344
Sansonno D, Carbone A, De Re V, Dammacco F (2007) Hepatitis C virus infection, cryoglobulinaemia, and beyond. Rheumatology (Oxford) 46(4):572–578
De Re V, De Vita S, Sansonno D et al (2006) Type II mixed cryoglobulinaemia as an oligo rather than a mono B-cell disorder: evidence from GeneScan and MALDI-TOF analyses. Rheumatology (Oxford) 45(6):685–693, 58
De Re V, De Vita S, Marzotto A et al (2000) Pre-malignant and malignant lymphoproliferations in an HCV-infected type II mixed cryoglobulinemic patient are sequential phases of an antigen-driven pathological process. Int J Cancer 87:211–216
Fu L, Lin-Lee YC, Pham LV et al (2006) Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood 107(11):4540–4548
Pham LV, Fu L, Tamayo AT et al (2011) Constitutive BR3 receptor signaling in diffuse large B-cell lymphomas stabilizes NF-{kappa}B-inducing kinase, while activating both canonical and alternative NF-{kappa}B pathways. Blood 117(1):200–210
De Re V, De Vita S, Sansonno D, Toffoli G (2008) Mixed cryoglobulinemia syndrome as an additional autoimmune disorder associated with risk for lymphoma development. Blood 111(12):5760
Libra M, De Re V, Gloghini A et al (2004) Detection of bcl-2 rearrangement in mucosa-associated lymphoid tissue lymphomas from patients with hepatitis C virus infection. Haematologica 89(7):873–874
Saadoun D, Suarez F, Lefrere F et al (2005) Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood 105:74–76
Ramos-Casals M, De Vita S, Tzioufas AG (2005) Hepatitis C virus, Sjögren’s syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer. Autoimmun Rev 4:8–15
Landau DA, Saadoun D, Calabrese LH, Cacoub P (2007) The pathophysiology of HCV induced B-cell clonal disorders. Autoimmun Rev 6(8):581–587
Dispenzieri A, Gorevic PD (1999) Cryoglobulinemia. Hematol Oncol Clin North Am 13(6):1315–1349
Levine W, Gota C, Fessler B et al (2005) Persistent cryoglobulinemic vasculitis following successful treatment of Hepatitis C Virus. J Rheumatol 32:1164–1167
La Civita L, Zignego AL, Lombardini F et al (1996) Exacerbation of peripheral neuropathy during alpha- interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection. J Rheumatol 23(9):1641–1643
Beuthien W, Mellinghoff HU, Kempis J (2005) Vasculitic complications of interferon-alpha treatment for chronic hepatitis C virus infection: case report and review of the literature. Clin Rheumatol 24(5):507–515
Quartuccio L, De Marchi G, Fabris M, De Vita S (2007) Development of type II mixed cryoglobulinaemic syndrome after effective and persistent hepatitis C virus eradication. Rheumatology (Oxford) 46(2):367–368
Carson DA, Chen PP, Fox RI et al (1987) Rheumatoid factor and immune networks. Annu Rev Immunol 5:109–126
Cambridge G, Isenberg DA, Edwards J et al (2008) B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 67(7):1011–1016
Cambridge G, Stohl W, Leandro MJ et al (2006) Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 54(3):723–732
Navarra S, Ilianova E, Bae SC, BLISS-52 Study Group, et al (2010) Belimumab, a BlyS-specific inhibitor reduced disease activity, flares and steroid use in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 study. Ann Rheum Dis 69(S1)
Furie RA, Gladman D, d’Cruz D et al (2010) Belimumab: a BLyS specific inhibitor, reduced disease activity and severe flares with seropositive SLE: BLISS-76 study. Lupus 19S:13
De Vita S, Quartuccio L (2010) Rituximab monotherapy, rather than rituximab plus antiviral drugs, for initial treatment of severe hepatitis C virus-associated mixed cryoglobulinemia syndrome: comment on the article by Terrier et al. Arthritis Rheum 62(3):908–909
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Italia
About this chapter
Cite this chapter
Fabris, M., De Vita, S. (2012). Up-Regulation of B-Lymphocyte Stimulator (BLyS) in Patients with Mixed Cryoglobulinemia. In: Dammacco, F. (eds) HCV Infection and Cryoglobulinemia. Springer, Milano. https://doi.org/10.1007/978-88-470-1705-4_15
Download citation
DOI: https://doi.org/10.1007/978-88-470-1705-4_15
Published:
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-1704-7
Online ISBN: 978-88-470-1705-4
eBook Packages: MedicineMedicine (R0)